Table 1 Characteristics of instrumental variable of exposure, outcome and confounders used for MR analysis
Type of variables | GWAS ID | Year | Trait | PMID | Author | Consortium | Population | Sample size | Number of SNPs |
|---|---|---|---|---|---|---|---|---|---|
Exposure | ebi-a-GCST002223 | 2013 | HDL cholesterol | 24,097,068 | Willer CJ | NA | European | 94,595 | 2,418,527 |
ebi-a-GCST90002412 | 2020 | LDL cholesterol | 32,493,714 | Klimentidis YC | NA | European | 431,167 | 16,293,344 | |
met-d-Total_C | 2022 | Total cholesterol | NA | Borges CM | NA | European | 115,078 | 12,321,875 | |
ebi-a-GCST002216 | 2013 | Triglycerides | 24,097,068 | Willer CJ | NA | European | 94,595 | 2,410,057 | |
Outcomes | finn-b-C3_OESOPHAGUS | 2021 | Esophageal cancer | NA | NA | NA | European | 218,792 | 16,380,466 |
finn-b-K11_BARRET | 2021 | Barret Esophagus | NA | NA | NA | European | 190,190 | 16,380,373 | |
Confounders | ebi-a-GCST90000514 | 2021 | Gastroesophageal reflux | 34,187,846 | Ong JS | NA | European | 602,604 | 2,320,781 |
ukb-b-2303 | 2018 | Body mass index | NA | Ben Elsworth | MRC-IEU | European | 454,884 | 9,851,867 |